More on Obesity Than GLP-1s at the ADA Scientific Sessions

Key Takeaways

• Retatrutide showed up to 28.3% weight loss in 80‑week phase 3
• Triple agonists target GIP, GLP‑1, and glucagon pathways simultaneously
• ADA session will feature over 12,000 professionals discussing obesity science
• New combos like CagriSema blend amylin with GLP‑1 activity
• Multi‑pathway drugs aim to improve glucose, appetite, and liver‑fat outcomes

Pulse Analysis

The upcoming ADA Scientific Sessions signal a turning point for obesity treatment, moving the conversation beyond the GLP‑1 class that has dominated headlines. While GLP‑1 receptor agonists remain central, the conference agenda reflects a deliberate shift toward multi‑receptor strategies that address the complex physiology of excess weight. By gathering more than 12,000 experts, the meeting underscores how intertwined diabetes and obesity have become, and how the industry is responding with a richer therapeutic toolbox.

Among the most anticipated data are Lilly’s retatrutide results, which reported an average 28.3% reduction in body weight after 80 weeks in the pivotal TRIUMPH‑1 trial. The drug’s triple‑agonist design—activating GIP, GLP‑1, and glucagon receptors—demonstrates the power of simultaneous pathway modulation, delivering both profound weight loss and meaningful A1C improvements in the TRANSCEND‑T2D‑1 study. Other pipeline candidates, such as CagriSema (amylin + GLP‑1), CT‑868 (GLP‑1/GIP), and petrelintide (amylin + calcitonin), further illustrate the industry’s commitment to diversifying mechanisms of action.

The broader implications extend to clinical practice, payer strategies, and health policy. Multi‑agonist therapies promise to address not only appetite but also metabolic inflammation, liver fat, and energy expenditure, potentially reducing the burden of obesity‑related complications. As efficacy data accumulate, insurers will weigh coverage decisions, while regulators may consider new endpoints for approval. Ultimately, the ADA sessions will provide a roadmap for how next‑generation obesity drugs could reshape treatment algorithms, expand market competition, and catalyze policy initiatives aimed at improving access to life‑changing therapies.